secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENERON PHARMACEUTICALS, INC. (REGN)
CIK:        0000872589
Form:       8-K
Filed at:   2022-06-02T23:59:59+00:00
Accession:  0001104659-22-067375
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Regeneron enters amended deal with Sanofi for full rights to Libtayo; pays $900M upfront
--------------------------------------------------------------------------------

- Regeneron gains sole worldwide rights to develop and commercialize Libtayo, effective upon regulatory approvals.
- Regeneron will pay Sanofi $900M upfront within 10 business days of effective date.
- Regeneron will pay an 11% royalty on Libtayo net sales through March 2034, plus up to $200M in milestone payments.
- Development cost reimbursement rate under Antibody LCA increased from 10% to 20% effective April 1, 2022.
- Transition services, distribution, and manufacturing agreements support the handover from Sanofi.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872589/000110465922067375/0001104659-22-067375-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872589/000110465922067375/tm2217255d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-067375

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer